Infectious Disease Archives - MPR

Infectious Disease

FDA Approves First-In-Class Antibiotic to Treat Community-Acquired Bacterial Pneumonia

The FDA has approved Xenleta (lefamulin; Nabriva Therapeutics) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.